IDXX 10-K Annual Reports

IDEXX Laboratories, Inc. (IDXX) reported strong financial performance for the year ended December 31, 2025, with total revenue reaching $4.30 billion, a 10.4% increase year-over-year. The Companion Animal Group (CAG) remains the primary revenue driver, contributing $3.95 billion, up 10.6% driven by strong recurring revenue from consumables and reference laboratory services. The company is strategically investing in Artificial Intelligence (AI) to enhance its diagnostic products and services, aiming to provide veterinarians with advanced tools for pet healthcare. Operational efficiency and strategic pricing contributed to a 11.8% increase in gross profit, with the gross profit margin improving to 61.8%. Despite inflationary pressures affecting product and labor costs, IDEXX demonstrated effective cost management, leading to a 20.5% increase in income from operations to $1.36 billion. The company also continued its share repurchase program, reflecting its commitment to returning value to shareholders. Looking ahead, IDEXX anticipates continued growth, though it acknowledges potential headwinds from macroeconomic factors and supply chain challenges, which it plans to manage through proactive strategies.

IDEXX Laboratories, Inc. (IDXX) reported solid financial performance for the fiscal year ended December 31, 2024, characterized by continued revenue growth and expanding gross profit margins. The company's primary segment, the Companion Animal Group (CAG), demonstrated resilience, with recurring diagnostic revenue comprising approximately 80% of consolidated revenue, highlighting the strength of its business model. Despite macroeconomic headwinds and sector-specific challenges such as reduced veterinary clinic capacity, IDEXX achieved organic revenue growth driven by price realization and steady customer retention. The company also saw growth in its Water business, while the Livestock, Poultry, and Dairy (LPD) segment remained largely stable. Investments in Research and Development remain a priority, with a focus on integrating Artificial Intelligence (AI) into its product and service offerings. Financially, IDEXX reported an increase in income from operations and maintained a strong gross profit margin of 61.0%. While operating expenses, particularly general and administrative costs due to litigation, saw an increase, the overall financial health appears robust. The company actively manages its capital structure, including share repurchases and maintaining a strong liquidity position with significant available borrowing capacity under its credit facility. IDEXX is well-positioned to continue investing in innovation and expanding its global reach, though it remains mindful of risks related to competition, supply chain disruptions, regulatory changes, and currency fluctuations.

IDEXX Laboratories, Inc. (IDXX) reported solid performance in its 2023 10-K filing, driven primarily by its Companion Animal Group (CAG). The company demonstrated robust revenue growth, with a notable increase in recurring revenues from consumables and services. This segment's strength, fueled by the ongoing demand for advanced veterinary diagnostics and information management solutions, significantly contributed to the overall financial health of the company. While the CAG segment showed strong organic growth, the Water segment also experienced positive revenue increases due to price adjustments and volume growth, bolstered by a strategic acquisition. The Livestock, Poultry, and Dairy (LPD) segment saw a slight revenue decline, influenced by external factors like reduced live animal imports. The 'Other' segment, primarily comprising human medical diagnostics, experienced a significant revenue drop due to the discontinuation of COVID-19 testing products. Overall, IDEXX continues to leverage its integrated diagnostic solutions and software offerings to enhance veterinary practice efficiency and patient care, positioning itself for continued success in the animal health market.

IDEXX Laboratories Inc. reported solid revenue growth of 4.7% to $3.37 billion for the fiscal year ended December 31, 2022. This growth was primarily driven by the Companion Animal Group (CAG), which saw an 8.4% organic revenue increase, demonstrating continued demand for veterinary diagnostics and services. Despite a slight decrease in clinical visits, revenue per practice grew, highlighting increased utilization of diagnostic products. The Water segment also showed positive organic growth of 9.7%. However, the Livestock, Poultry, and Dairy (LPD) segment experienced a decline, largely due to reduced demand in China for swine testing. Research and development expenses saw a significant increase (58.3%) due to strategic investments in technology licensing. The company highlighted its strong gross profit margin of 59.5%, supported by price gains and efficiency initiatives, though facing increased costs in freight, distribution, and labor. IDEXX also actively managed its capital through share repurchases and a $1.25 billion credit facility, ending the year with $112.5 million in cash and cash equivalents. The company remains focused on innovation, customer relationships, and operational efficiency to navigate a competitive landscape and maintain long-term value creation for shareholders.

IDEXX Laboratories, Inc. (IDXX) demonstrated robust financial performance in its 2021 annual report, with total revenues reaching $3.22 billion, an 18.8% increase year-over-year. This growth was primarily driven by the Companion Animal Group (CAG), which saw a 21.1% revenue increase, fueled by strong recurring diagnostic revenues and a rebound in instrument placements. The company's strategic focus on integrated diagnostic solutions and software services continues to yield positive results, enhancing customer loyalty and driving demand for consumables and services. Despite global supply chain and logistics challenges, IDEXX maintained operational efficiency and product availability. The company also highlighted its commitment to innovation and customer service, which are key differentiators in the competitive veterinary diagnostics market. While the 'Other' segment, including human diagnostics, saw a revenue decline, largely due to a reduction in COVID-19 testing, the core CAG business remains the primary growth engine. IDEXX's strong cash flow generation and ample liquidity position it well to continue investing in growth initiatives and returning value to shareholders through its share repurchase program.

IDEXX Laboratories, Inc. (IDXX) reported robust performance in its 2020 fiscal year, driven by strong growth in its Companion Animal Group (CAG) segment. Despite initial impacts from the COVID-19 pandemic, the company demonstrated resilience, with significant recovery and growth in the latter half of the year, particularly in recurring diagnostic revenues. The company's diversification across veterinary diagnostics, water testing, and livestock/poultry diagnostics provided stability, while its "Other" segment saw a substantial boost from COVID-19 testing solutions. Financially, IDEXX maintained a strong balance sheet with increased cash reserves and available borrowing capacity, supporting ongoing operations and strategic initiatives. The company's focus on innovation, integrated solutions, and strong customer relationships continues to be a key driver of its competitive advantage and financial success. Investors should note the company's strategic emphasis on recurring revenue streams, particularly consumables and services within the CAG segment, which offer higher margins and greater predictability.

IDEXX Laboratories, Inc. (IDXX) reported strong performance in its 2019 fiscal year, characterized by robust revenue growth driven primarily by its Companion Animal Group (CAG) segment. The company demonstrated a consistent upward trend in both reported and organic revenue, with a notable increase in gross profit margin attributed to favorable product mix, volume leverage, and price increases in recurring revenue streams. Investments in research and development remain a priority, indicating a focus on continued innovation and market leadership. The company's financial health appears solid, with healthy operating income and a strong balance sheet, although it manages a significant amount of long-term debt. IDEXX also actively engages in share repurchases, returning value to shareholders and offsetting the dilutive effects of equity-based compensation. Looking ahead, IDEXX is focused on expanding its installed base of diagnostic instruments, driving recurring revenue from consumables and services, and leveraging its integrated technology platforms to enhance veterinary care and practice efficiency. The company remains optimistic about its growth prospects across its key segments.

IDEXX Laboratories, Inc. (IDXX) reported strong financial performance for the fiscal year ended December 31, 2018, driven by its dominant Companion Animal Group (CAG) segment. The company demonstrated robust revenue growth, with a significant portion attributed to recurring diagnostic revenues from consumables and services. Continued investment in research and development fuels innovation, supporting competitive advantages in diagnostic accuracy, ease of use, and integrated information management systems for veterinarians. Despite facing competition and global economic uncertainties, IDEXX has a diversified business model spanning veterinary, water, and livestock diagnostics. The company's strategic focus on customer loyalty programs, technological advancements, and expanding its global commercial infrastructure positions it for sustained growth. Management emphasizes the ongoing development of advanced diagnostic technologies and software integration, reinforcing its value proposition to veterinarians and ultimately enhancing pet and livestock health.

IDEXX Laboratories, Inc. (IDXX) reported strong performance in its 2017 10-K filing, demonstrating robust revenue growth driven primarily by its Companion Animal Group (CAG) segment. The company's strategy of providing integrated diagnostic solutions and leveraging recurring revenue streams from consumables and services continues to be effective. Significant investments in research and development, alongside a focus on innovation, position IDEXX for continued leadership in the veterinary diagnostics market. The company's financial health appears solid, with positive operating income and a healthy cash position. While facing competitive pressures and global economic uncertainties, IDEXX's diversified business model across veterinary, water, and livestock sectors, along with its strategic focus on technological advancements and customer value, provides a strong foundation for future growth. The filing also highlights the company's proactive approach to adopting new accounting standards and managing market risks, including currency fluctuations.

IDEXX Laboratories, Inc. (IDXX) reported strong financial performance for the fiscal year ended December 31, 2016, with revenue growth driven primarily by its Companion Animal Group (CAG) segment. The company experienced a 10.8% increase in total revenue to $1.775 billion, with organic revenue growth of 11.4%. This growth was fueled by robust performance in recurring diagnostic revenue streams, including consumables and reference laboratory services, as well as increased placements of capital instruments like the SediVue Dx analyzer. The company also saw growth in its Water segment, while the Livestock, Poultry and Dairy (LPD) segment experienced a slight revenue decline. IDEXX continued its strategic shift towards a direct-to-customer sales model in the U.S., which management believes strengthens customer loyalty and supports long-term growth. The company also demonstrated a commitment to shareholder returns through active share repurchases. Despite challenges such as foreign currency fluctuations and increased competition, IDEXX's diversified business model and focus on innovation position it for continued success in its core veterinary markets.

IDEXX Laboratories, Inc. (IDXX) reported strong revenue growth for the fiscal year ending December 31, 2015, driven primarily by its Companion Animal Group (CAG) segment. The company's strategic shift to an all-direct sales model in the U.S. for certain products, implemented at the beginning of 2015, appears to be positively impacting revenue and customer relationships, despite initial transition costs. International sales continue to be a significant contributor to overall revenue, although the strengthening U.S. dollar presented a headwind. The company maintained a focus on innovation, with new product introductions and continued investment in research and development. Financial performance demonstrated growth in gross profit and operating income, excluding certain one-time transition costs. The company's commitment to returning value to shareholders is evident through its ongoing share repurchase program, with no intention to pay dividends at this time. IDEXX's diversified business across veterinary diagnostics, water testing, and livestock/poultry/dairy markets, coupled with its strong market position, provides a resilient business model. Investors should note the company's ongoing efforts to expand its product offerings and its management of supply chain and competitive risks.

IDEXX Laboratories, Inc. (IDXX) for the fiscal year ending December 31, 2014, reported strong revenue growth, primarily driven by its Companion Animal Group (CAG). The company emphasized its "IDEXX Diagnostic Advantage," a strategy focused on integrated diagnostic and information management solutions for veterinarians. This integrated approach aims to enhance veterinary care, improve practice efficiency, and strengthen the veterinarian-client relationship. The company's strategic shift to an all-direct sales model in the U.S. for certain products is expected to drive further revenue growth and profitability, despite some near-term transition costs. Financially, IDEXX demonstrated solid performance with increasing revenues across most segments. The company continued to invest in research and development, indicating a commitment to innovation. While facing competitive pressures, IDEXX's diversified product portfolio across veterinary diagnostics, water testing, and livestock/poultry health provides a degree of resilience. The company also managed its balance sheet effectively, utilizing its credit facilities and debt issuances to fund growth and shareholder returns through a robust share repurchase program, as they have not paid cash dividends.

IDEXX Laboratories, Inc. (IDXX) reported robust revenue growth for the fiscal year ending December 31, 2013, demonstrating resilience and continued expansion across its core business segments. The company's strategic focus on its Companion Animal Group (CAG) continues to yield strong results, driven by recurring revenue from consumables and services, complemented by the placement of new diagnostic instruments. The diversification into Water and Livestock, Poultry, and Dairy (LPD) segments also contributes to overall financial health, although performance in these areas shows varying trends. IDEXX's commitment to innovation and product development is evident through its ongoing research and development investments, aiming to further solidify its market leadership and drive future growth. Financially, the company exhibits a healthy balance sheet with growing cash reserves and effective management of operating expenses. IDEXX actively returned capital to shareholders through a significant share repurchase program and demonstrated its ability to access capital markets effectively, as evidenced by the issuance of senior notes. The company's operational efficiency and strategic execution position it for sustained performance in the dynamic veterinary and diagnostic markets.

IDEXX Laboratories, Inc. (IDXX) reported its 2012 annual results, showcasing continued revenue growth driven primarily by its Companion Animal Group (CAG). The company's strategy of offering integrated diagnostic and information management solutions for veterinary practices appears to be resonating with customers. While the overall economic climate presented some headwinds, particularly in certain international markets and impacting capital expenditures by veterinarians, IDEXX demonstrated resilience. Key growth drivers included strong performance in reference laboratory services and consumables for its in-clinic diagnostic instruments. The company also highlighted its ongoing investment in research and development, evident in product launches and platform enhancements. Despite the challenging economic environment, IDEXX maintained a solid financial position with growing revenues and a healthy operating income. The company's diversified business segments, including Water and Livestock and Poultry Diagnostics, contributed to its overall performance, although LPD experienced a decline due to regulatory changes. IDEXX's commitment to innovation and expanding its product and service offerings positions it for continued relevance in the animal health and diagnostics markets.

IDEXX Laboratories, Inc. (IDXX) filed its 2011 10-K on February 16, 2012, providing a comprehensive overview of its business operations, financial condition, and strategic outlook. As a global leader in diagnostics and information technology for veterinarians, the company's performance is closely tied to the health of the companion animal market and the veterinary industry's adoption of advanced diagnostic tools. Investors should pay close attention to the company's revenue growth drivers, particularly within its key segments like Companion Animal Group and Water, where innovation and market penetration are crucial. The filing highlights the company's commitment to research and development, which fuels its product pipeline and competitive advantage. Management's Discussion and Analysis will likely offer insights into the company's financial performance, including revenue trends, profitability, and cash flow generation, alongside a discussion of the risks and uncertainties that could impact future results. Investors should review these sections carefully to understand the company's resilience and growth prospects in the dynamic animal health and laboratory diagnostics sectors.

IDEXX Laboratories, Inc. (IDXX) presented its 2010 annual report on Form 10-K, highlighting a year of robust revenue growth driven primarily by its Companion Animal Group (CAG) segment. The company's diversified product and service offerings, including diagnostic and information technology solutions for veterinary practices, water testing, and livestock and poultry diagnostics, demonstrated resilience. IDEXX continued to invest in research and development, launching new products like the ProCyte Dx™ hematology analyzer and focusing on enhancing its integrated diagnostic solutions. The company also managed supply chain dependencies and faced competitive pressures, while navigating an evolving economic landscape. The report indicates a strong operational performance with a focus on innovation and market expansion.

IDEXX Laboratories, Inc. filed its 2009 10-K on February 18, 2010, detailing its business operations, financial performance, and risk factors for the fiscal year ending December 30, 2009. The company operates in the veterinary diagnostics and animal health industry. Investors should pay close attention to Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations, which provides critical insights into the company's performance drivers, strategic initiatives, and outlook. The report also incorporates by reference its definitive proxy statement for the upcoming 2010 Annual Meeting, which will contain further details on corporate governance and executive compensation. While specific financial figures are not detailed in the provided excerpt, the structure of the 10-K indicates a comprehensive review of IDEXX's business segments, competitive landscape, and any material risks or legal proceedings that could impact its future profitability and market position. Investors are encouraged to review the full filing, particularly the financial statements and MD&A, to understand the company's financial health and strategic direction.

IDEXX Laboratories Inc. filed its 2008 10-K report on February 19, 2009, providing a comprehensive overview of its business operations and financial performance for the fiscal year ending December 30, 2008. The report details the company's activities within the animal health industry, focusing on its diagnostic and information technology solutions for veterinarians. Investors can gain insights into IDEXX's market position, competitive landscape, and strategic direction through this filing. Key sections of the report, such as "Business," "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations," offer critical information regarding the company's revenue streams, profitability, and challenges. The filing also includes detailed financial statements, providing a transparent look at the company's assets, liabilities, and equity. While the provided excerpt is a table of contents, it indicates that the full report delves into crucial aspects like market risks, corporate governance, and executive compensation, which are vital for a thorough investor assessment.

IDEXX Laboratories, Inc. (IDXX) reported robust financial performance for the fiscal year ending December 31, 2007. The company demonstrated significant revenue growth, driven by strong performance across its key segments, particularly the Companion Animal Group (CAG). Total revenue increased to $922.6 million, a substantial rise from $739.1 million in 2006, indicating successful market penetration and product acceptance. The company's strategic acquisitions also played a crucial role in its expansion, contributing to a notable increase in goodwill and intangible assets on the balance sheet. Despite increased investment in property and equipment and acquisitions, IDEXX maintained healthy profitability and cash flow generation. The company's financial position appears solid, with a growing equity base and effective management of its debt facilities. Investors can look to IDEXX's continued focus on innovation and market expansion as key drivers for future growth.

IDEXX Laboratories, Inc. (IDXX) reported strong revenue growth of 16% to $739.1 million for the fiscal year ended December 30, 2006. This growth was primarily driven by its Companion Animal Group (CAG), which saw a 16.4% revenue increase, fueled by instruments, consumables, rapid assays, and laboratory services. The company also experienced robust growth in its Production Animal Segment (PAS), up 31.1%. While gross profit margins remained stable around 51.3%, operating expenses increased, partly due to the adoption of new accounting standards for share-based compensation (SFAS No. 123(R)), which impacted reported expenses and operating income margins. Despite these factors, operating income grew by 10.9% year-over-year. IDEXX continues to invest in research and development, with R&D expenses increasing to 7.3% of sales, signaling a commitment to innovation in diagnostic platforms and new tests. The company also actively pursues strategic acquisitions, notably the recent addition of the Critical Care Division of Osmetech plc for its human point-of-care diagnostics market and the planned acquisition of Institut Pourquier for its production animal diagnostics business. While facing competition and regulatory hurdles, IDEXX's diversified business model across veterinary, water, and production animal health markets, coupled with ongoing product development and strategic acquisitions, positions it for continued growth.

IDEXX Laboratories, Inc. (IDXX) presented its fiscal year 2005 performance in this 10-K filing. The company demonstrated robust revenue growth, increasing by 16% to $638.1 million, driven primarily by its Companion Animal Group (CAG). This segment saw a significant 16.1% revenue increase, fueled by strong performance in instruments and consumables, rapid assays, and a substantial 31.9% surge in reference laboratory and consulting services, bolstered by strategic acquisitions. The company also reported positive growth in its Water and Food Diagnostics Groups (FDG), with FDG showing a notable 27.7% revenue increase. IDEXX maintained a stable gross profit margin of approximately 50.8% in 2005, reflecting its ability to manage costs effectively amidst growth and integration activities. Despite an increase in operating expenses, partly due to acquisition integration and expanded sales efforts, the company achieved a solid operating income, though the operating income margin slightly decreased. IDEXX continues to invest in research and development, signaling a commitment to future innovation and market leadership in the animal health and diagnostics sectors.

IDEXX Laboratories, Inc. (IDXX) reported strong performance for the fiscal year ended December 31, 2004, with total revenue increasing by 15.4% to $549.2 million. This growth was primarily driven by the Companion Animal Group (CAG), which saw a 16.7% revenue increase, bolstered by strong performance in laboratory and consulting services, as well as instruments and consumables. The company's strategic focus on integrated diagnostic solutions for veterinary practices continues to yield positive results, evidenced by increasing adoption of its IDEXX VetLab® suite and digital radiography systems. The company also demonstrated improved profitability, with gross profit increasing by 21.2% and gross profit margin expanding to 50.8% from 48.4% in the prior year. This margin expansion was attributed to productivity improvements, favorable currency exchange rates, and optimized supplier agreements. Operating expenses grew at a controlled rate, leading to a significant 34.4% increase in operating income. IDEXX continues to invest in research and development, focusing on new product innovation and enhancements to existing offerings, positioning itself for sustained growth in the veterinary diagnostics and companion animal health markets.

IDEXX Laboratories Inc. (IDXX) reported robust financial performance for the fiscal year ending December 30, 2003, demonstrating significant revenue growth driven by its Companion Animal Group (CAG), which accounts for the majority of sales. The company achieved a 15% increase in total revenue, reaching $476 million, with CAG sales growing by 18% to $384 million. This growth was fueled by strong performance in instruments, consumables, rapid assays, and laboratory services within the CAG segment, indicating increased adoption and utilization of IDEXX's diagnostic solutions by veterinary professionals. The company also saw moderate growth in its Water testing business and Food Diagnostics Group, though these segments represent smaller portions of overall revenue. IDEXX's strategic focus on providing integrated diagnostic products and services, coupled with investments in new product development and market expansion, appears to be paying off. Despite facing competitive markets and technological advancements, IDEXX's strong revenue performance and improving gross profit margins suggest a resilient business model and a solid position within the animal health and diagnostics industries.

IDEXX Laboratories, Inc. (IDXX) filed its 2002 Form 10-K on March 20, 2003, detailing a year of steady revenue growth, primarily driven by its Companion Animal Group (CAG), which accounted for 79% of total sales. The company reported total revenue of $412.7 million for the year ended December 31, 2002, a 7% increase from the prior year. This growth was fueled by strong performance in laboratory services, instrument consumables, and rapid assay products within the veterinary diagnostics sector. The company continues to invest in research and development, with expenses totaling $29.3 million in 2002, focusing on new diagnostic platforms, animal drugs, and improved testing products. IDEXX also highlighted the successful adoption of SFAS No. 142, which eliminated goodwill amortization, positively impacting its effective tax rate. While the company faces competition and regulatory scrutiny, its financial position appears robust, with significant cash and investments and a commitment to reinvesting earnings for future growth, as no dividends are currently paid.

IDEXX Laboratories, Inc. (IDXX) reported fiscal year 2001 results, showcasing revenue growth driven primarily by its Companion Animal Group (CAG) segment, which includes veterinary diagnostic products and services. The company continues to expand its product offerings, particularly in point-of-care diagnostics and veterinary pharmaceuticals, with recent FDA approval for its first drug, ACAREXX. While overall revenue increased, the company faces ongoing challenges including intense competition, rapid technological changes, and the complexities of global regulatory environments. IDEXX is actively managing its supply chain, particularly for key components of its diagnostic instruments, and is investing in research and development to fuel future growth, with notable upcoming product launches like the LaserCyte hematology system. The company's financial position remains solid, with sufficient liquidity to fund operations and strategic initiatives, and it continues to prioritize reinvestment in its business over dividend payments.

IDEXX Laboratories, Inc. (IDXX) presents its 2000 Form 10-K, detailing robust performance primarily driven by its Companion Animal Group (CAG). CAG, encompassing veterinary diagnostics, pharmaceuticals, and informatics, saw revenue growth fueled by increased reference laboratory services, consumables, and test kits. Despite a slight dip in gross margin percentage due to a higher mix of lower-margin services, overall operating expenses remained controlled, largely due to strategic expense management and the ongoing development of its internet platform for animal health professionals. The Food and Environmental Division (FED) experienced a revenue decline, primarily attributed to the divestiture of its food microbiology testing business. However, gross margins within FED improved significantly due to the disposal of the lower-margin business and growth in higher-margin water testing products. The company continues to invest in research and development, focusing on new diagnostic systems, enhanced information solutions, and novel veterinary therapeutics, positioning itself for future growth and innovation in the animal health sector.

IDEXX Laboratories, Inc. filed its 2000 annual report (10-K) for the fiscal year ended December 30, 1999. While the provided text is primarily navigational content from the SEC EDGAR database and does not contain the specific financial details of the 10-K, it confirms the filing date and period. Investors would typically look to the actual 10-K document for critical information regarding financial performance, revenue streams, profitability, balance sheet health, cash flow, and management's discussion and analysis of results and outlook. Without the content of the actual financial statements and footnotes, a detailed analysis is not possible. However, based on the company's known business in veterinary diagnostics and related products, investors would be keen to understand growth trends in their core segments, any new product introductions or competitive pressures, and the company's strategic direction for expanding its market reach and profitability in the coming fiscal year.